今年以来大洋生物已经1次登上龙虎榜，最近一次登上龙虎榜为6月16日。 资料显示，浙江大洋生物科技集团股份有限公司位于浙江省杭州市建德市大洋镇朝阳路22号，成立日期 1976年1月1日，上市日期2020年10月26日，公司主营业务涉及从事无机盐、兽用原料药等化学原料产品 的生产和销售。主营业务收入构成为：无机盐产品69.91%，兽用原料药18.35%，含氟化学品7.46%，其 他产品4.28%。 9月10日，大洋生物盘中下跌2.02%，截至10:09，报35.42元/股，成交6750.71万元，换手率2.70%，总市 值29.75亿元。 资金流向方面，主力资金净流出334.41万元，特大单买入290.42万元，占比4.30%，卖出507.71万元，占 比7.52%；大单买入1451.10万元，占比21.50%，卖出1568.22万元，占比23.23%。 大洋生物今年以来股价涨93.30%，近5个交易日跌0.76%，近20日涨5.04%，近60日涨25.07%。 责任编辑：小浪快报 大洋生物所属申万行业为：基础化工-化学原料-无机盐。所属概念板块包括：送转填权、化肥、氟化 工、生物农药、增持回购等。 分红方面，大 ...

Group 1 - The average price and sales volume of hydrochloride aminophenol have increased compared to the same period last year [2] - The new production line for hydrochloride aminophenol, with a capacity of 800 tons per year, is still under construction [2] - The specific production timeline and output details will be disclosed by the company in public announcements [2]

Group 1: Potassium Carbonate and Bicarbonate Industry - Potassium carbonate is a key raw material in various industries including chemicals, pharmaceuticals, pesticides, light industry, and food [1] - The company is a leading player in the potassium carbonate and bicarbonate industry, recognized as a national high-tech enterprise and a "little giant" enterprise [1] - The production of potassium bicarbonate is increasingly utilized in food as an acidity regulator and chemical leavening agent, with growing consumption driven by health awareness [1] Group 2: Amprolium Hydrochloride Application - Amprolium hydrochloride is primarily used in poultry, cattle, and sheep, with increasing demand due to rising per capita consumption of poultry meat and the solidification of large-scale farming practices [2] - The company's clean production project for amprolium hydrochloride has been recognized as a "National Torch Program Industrialization Demonstration Project" [2] - The production process incorporates resin adsorption and distillation to address wastewater treatment challenges, showcasing significant environmental advantages [2] Group 3: Fluorochemical Industry Potential - The fluorochemical sector, including fluorinated intermediates, pharmaceuticals, pesticides, dyes, and surfactants, has substantial development potential [3] - The company has over 30 years of experience in fluorochemical production, being a major supplier of 2-chloro-6-fluoro series products in both domestic and international markets [3] - The company possesses pilot technology for PEEK intermediates, which have excellent comprehensive performance [3]

Group 1 - The A-share chemical sector experienced a strong rebound on September 8, with notable stocks such as Jinjing Technology hitting the daily limit up [1] - Dayang Biological surged over 5%, while Jiangshan Co., Lier Chemical, and Yangnong Chemical also saw increases [1]

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 1, 1976, and listed on October 26, 2020 [2] - The company primarily engages in the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [2] - The revenue composition is as follows: Inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine chemicals 7.46%, and other products 4.28% [2] Stock Performance - As of September 4, the stock price of Dayang Biological fell by 2.21% to 34.90 CNY per share, with a market capitalization of 2.932 billion CNY [1] - Year-to-date, the stock price has increased by 90.46%, with a 5-day increase of 8.59%, a 20-day increase of 10.72%, and a 60-day increase of 41.07% [2] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on June 16 [2] Financial Performance - For the first half of 2025, Dayang Biological achieved a revenue of 499 million CNY, representing a year-on-year growth of 14.20% [2] - The net profit attributable to the parent company was 50.51 million CNY, showing a year-on-year increase of 60.66% [2] - Cumulative cash dividends since the A-share listing amount to 168 million CNY, with 97.57 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders increased to 14,200, a rise of 58.33% from the previous period [2] - The average number of tradable shares per shareholder decreased by 35.82% to 4,954 shares [2] Market Position - Dayang Biological is classified under the Shenwan industry category of basic chemicals - chemical raw materials - inorganic salts [2] - The company is associated with several concept sectors, including raw materials, synthetic biology, fluorine chemicals, share buybacks, and small-cap stocks [2]

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本公告日前十二个月公司使用闲置募集资金进行现金管理的情况 截至本公告日，公司及子公司使用闲置募集资金进行现金管理尚未到期的金 额为人民币 11,000.00 万元，未超出公司第六届董事会第五次会议关于使用闲置募 集资金进行现金管理的授权额度。截至本公告日，公司使用闲置募集资金进行现 金管理具体情况如下： | | | | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 申 | 签 | | | | 产 | | 起 | | 到 | | | 是 | | 序 | 购 | 约 | | | | 品 | 认购金 | | 息 | | 期 | 预期年化 | | | 收 | | | 否 | 投资 | | | | | | | | | | | | ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2025 年 8 月 22 日召开第六届董事会第五次会议、第六届监事会第 五次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议案》。 根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响募投项 目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下简称"福 建舜跃"）使用最高额度不超过 12,000.00 万元（含本数）闲置募集资金进行现金 管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月之内有效。具 体内容详见公司在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于继续使用部分闲置募集资金进行 ...

Market Overview - On September 1, the chemical raw materials sector rose by 0.86% compared to the previous trading day, with Dayang Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Performers - Dayang Biological (003017) closed at 36.51, up 8.18% with a trading volume of 148,800 shares and a transaction value of 537 million yuan [1] - Jinpu Titanium Industry (000545) closed at 3.27, up 5.48% with a trading volume of 767,500 shares [1] - Luxi Chemical (000830) closed at 15.31, up 5.22% with a trading volume of 597,600 shares and a transaction value of 904 million yuan [1] Underperformers - ST Yatai (000691) closed at 6.63, down 5.01% with a trading volume of 135,300 shares and a transaction value of 90.07 million yuan [2] - Kaisheng New Materials (301069) closed at 22.18, down 2.08% with a trading volume of 141,200 shares [2] - Beiyuan Group (601568) closed at 4.12, down 1.67% with a trading volume of 463,700 shares [2] Capital Flow - The chemical raw materials sector experienced a net outflow of 108 million yuan from institutional investors, while retail investors saw a net outflow of 113 million yuan [2] - However, speculative funds recorded a net inflow of 221 million yuan [2] Individual Stock Capital Flow - Luxi Chemical (000830) had a net inflow of 76.93 million yuan from institutional investors, while it faced a net outflow of 104 million yuan from retail investors [3] - Dayang Biological (003017) saw a net inflow of 56.91 million yuan from institutional investors but a net outflow of 57.61 million yuan from speculative funds [3] - Zhongke Titanium White (002145) had a net inflow of 45.07 million yuan from institutional investors, with a net outflow of 48.10 million yuan from retail investors [3]

Core Viewpoint - Zhejiang Dayang Biological Technology Group Co., Ltd. announced a share reduction plan by its actual controllers and their concerted actors, which involves a total reduction of up to 839,123 shares, accounting for 1.00% of the company's total share capital [1][2][3]. Summary by Sections Shareholders' Information - The total number of shares held by the concerted actors is 2,140,518 shares, representing 2.56% of the company's total share capital [2]. - Individual holdings include: - Mr. Hao Bingyan: 1,123,595 shares (1.34%) - Mr. Qian Jianchun: 770,000 shares (0.92%) - Mr. Chen Shouliang: 199,123 shares (0.24%) - Ms. Zhao Yumei: 47,800 shares (0.06%) [1]. Reduction Plan Details - The share reduction will occur within three months following the announcement, excluding periods when reductions are prohibited by the Shenzhen Stock Exchange [1][3]. - The shares to be reduced are from those acquired before the company's IPO and through capital reserve conversion [2][3]. Compliance and Commitments - The shareholders have committed to not transferring or entrusting their shares for 36 months post-IPO, with specific conditions for any subsequent reductions [4]. - The shareholders have adhered to their commitments without any violations of regulations or agreements [4][5]. Impact on Company Governance - The planned share reduction will not lead to a change in control of the company and is not expected to significantly impact the company's governance structure or ongoing operations [5].

Group 1 - The actual controllers of Dayang Biotechnology plan to reduce their shareholding by a total of approximately 840,000 shares, not exceeding 1% of the company's total share capital, within three months after the disclosure of the share reduction plan [1] - As of the announcement date, the shareholding details are as follows: Mr. Hao Bingyan holds approximately 1.34% of the total shares, Mr. Qian Jianchun holds 0.92%, Mr. Chen Shouliang holds 0.24%, and Ms. Zhao Yumei holds 0.06% [1] - For the first half of 2025, Dayang Biotechnology's revenue composition is 95.72% from the chemical industry and 4.28% from other sources [1] Group 2 - Dayang Biotechnology has a market capitalization of 2.7 billion yuan [1]